Founded on the September 18th, 2017 Priavoid GmbH  is headquartered in Jülich, near Düsseldorf, Germany.

Priavoid is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the Central Nervous System (CNS).

We develop novel therapies for the treatment of neurological diseases based on all-D-peptides. The most advanced drug in our pipeline is PRI-002, a Phase I clinical trial candidate for the treatment of Alzheimer’s disease. The treatment strategy of PRI-002 differs from conventional approaches in that the so-called „toxic oligomers“ – that is the probable cause of the neurodegenerative disease – are eliminated in the presence of the drug candidate. The oral administration of PRI-002 leads to improved cognitive behavior in three different transgenic mouse models.